[go: up one dir, main page]

AR018252A1 - Forma de dosificacion farmaceutica en particulas solidas adecuada para suministro oral. - Google Patents

Forma de dosificacion farmaceutica en particulas solidas adecuada para suministro oral.

Info

Publication number
AR018252A1
AR018252A1 ARP980104098A ARP980104098A AR018252A1 AR 018252 A1 AR018252 A1 AR 018252A1 AR P980104098 A ARP980104098 A AR P980104098A AR P980104098 A ARP980104098 A AR P980104098A AR 018252 A1 AR018252 A1 AR 018252A1
Authority
AR
Argentina
Prior art keywords
dosage form
solid particles
pharmaceutical dosage
particles suitable
oral supply
Prior art date
Application number
ARP980104098A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR018252A1 publication Critical patent/AR018252A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Dispersiones de partículas solidas de agentes farmacéuticos en una matriz de un polímero soluble en agua que exhiben buena disolucion acuosay aumento de biodisponibilidad.
ARP980104098A 1997-08-21 1998-08-19 Forma de dosificacion farmaceutica en particulas solidas adecuada para suministro oral. AR018252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5619597P 1997-08-21 1997-08-21

Publications (1)

Publication Number Publication Date
AR018252A1 true AR018252A1 (es) 2001-11-14

Family

ID=22002810

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104098A AR018252A1 (es) 1997-08-21 1998-08-19 Forma de dosificacion farmaceutica en particulas solidas adecuada para suministro oral.

Country Status (17)

Country Link
US (1) US20010048946A1 (es)
EP (1) EP1011640A1 (es)
JP (1) JP2001515029A (es)
KR (1) KR20010023085A (es)
AR (1) AR018252A1 (es)
AU (1) AU8600098A (es)
BR (1) BR9811972A (es)
CA (1) CA2292586C (es)
CO (1) CO4960652A1 (es)
GT (1) GT199800136A (es)
HN (1) HN1998000115A (es)
NZ (1) NZ502869A (es)
PA (1) PA8458101A1 (es)
PE (1) PE109599A1 (es)
SV (1) SV1998000104A (es)
WO (1) WO1999008660A1 (es)
ZA (1) ZA987551B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018106A1 (en) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Method of manufacturing solid dispersion
JPH06511291A (ja) * 1991-08-02 1994-12-15 ウィルコム　タフティング　ピーティーワイ　リミテッド 房付け方法及び房付けシステム
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
JP2003518485A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
JP4997683B2 (ja) * 2000-09-25 2012-08-08 日本新薬株式会社 医薬固体分散体の製法
ATE293439T1 (de) * 2000-12-07 2005-05-15 Warner Lambert Co Verfahren und system zur gleichmä igen arzneistoffabgabe
EP1404300B1 (en) 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
MXPA04007438A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
EP2111856A3 (en) 2002-08-12 2014-09-10 Bend Research, Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
US8273371B2 (en) * 2003-06-27 2012-09-25 Johan Adriaan Martens Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1648416A4 (en) * 2003-07-18 2012-03-28 Santarus Inc PHARMACEUTICAL FORMULATIONS FOR INHIBITING THE ACIDIC ACIDIFICATION AND MANUFACTURING AND USE METHOD
CA2532931A1 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
AU2004294817B2 (en) * 2003-12-04 2007-01-25 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2007001451A2 (en) 2004-11-09 2007-01-04 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
ES2401992T3 (es) * 2004-12-30 2013-04-26 Pierre Fabre Medicament Dispersión sólida estable de un derviado de alcaloide de vinca y procedimiento para su preparación
FR2880274B1 (fr) * 2004-12-30 2007-04-13 Pierre Fabre Medicament Sa Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication
US20100152299A1 (en) * 2005-05-10 2010-06-17 Madhav Vasanthavada Process for making compositions with poorly compressible therapeutic compounds
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
AU2007335191A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical compound and composition
RU2491918C2 (ru) * 2008-07-03 2013-09-10 Новартис Аг Способ грануляции из расплава
WO2010136604A1 (en) * 2009-05-29 2010-12-02 Dsm Ip Assets B.V. Transfer matrix for transferring a bioactive agent to body tissue
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法
EP2765993B1 (en) * 2011-09-14 2020-05-20 Amgen (Europe) GmbH Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2, 3-dihydro-1h-isoindol-4-yl}-amide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPH054919A (ja) * 1990-07-25 1993-01-14 Sankyo Co Ltd チアゾリジン誘導体の固体分散体
WO1992018106A1 (en) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Method of manufacturing solid dispersion
JP3722293B2 (ja) * 1991-12-18 2005-11-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 新規な薬学的固体分散物
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
JPH07324086A (ja) * 1994-05-31 1995-12-12 Sankyo Co Ltd チアゾリジン誘導体の固体分散体または固体分散体製剤
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
HN1998000115A (es) 1999-06-02
BR9811972A (pt) 2000-08-15
CO4960652A1 (es) 2000-09-25
KR20010023085A (ko) 2001-03-26
SV1998000104A (es) 1999-07-02
PA8458101A1 (es) 2001-12-14
GT199800136A (es) 2000-02-11
AU8600098A (en) 1999-03-08
JP2001515029A (ja) 2001-09-18
WO1999008660A1 (en) 1999-02-25
NZ502869A (en) 2002-10-25
US20010048946A1 (en) 2001-12-06
ZA987551B (en) 1999-02-23
PE109599A1 (es) 1999-12-19
CA2292586C (en) 2006-02-14
EP1011640A1 (en) 2000-06-28
CA2292586A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
AR018252A1 (es) Forma de dosificacion farmaceutica en particulas solidas adecuada para suministro oral.
JP2001515029A5 (es)
MXPA05007158A (es) Formulacion farmaceutica con un agente activo insoluble.
CO5611097A2 (es) Tableta farmaceutica
AU2155199A (en) Microparticles for drug delivery across mucosa and the blood-brain barrier
ES2177346T3 (es) Formulaciones de ranolazina de liberacion lenta.
MX9300998A (es) Sistema mejorado de liberacion farmaceutica y metodo para su preparacion.
ATE253894T1 (de) Pharmazeutische suspensionssysteme
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
ATE333265T1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
CU23440B7 (es) Composición de liberación sostenida de pramipexol
MY135852A (en) Pharmaceutical products
DK1348429T3 (da) Smelteekstruderede opioidformuleringer, der kan administreres oralt
AR030862A1 (es) Formulaciones medicinales en aerosol
EP2298279A3 (en) Pharmaceutical compositions for inhalation
AU4989997A (en) Soluble form osmotic dose delivery system
UY24888A1 (es) Tabletas de oxacarbazepina recubiertas de pelicula
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
NO996323L (no) Medisinske blandinger for anvendelse på mukosa
HRP20020091B1 (en) ?-carboline drug products
EP1135106A4 (en) PROLONGED RELEASE MATRIX SYSTEMS FOR HIGHLY SOLUBLE DRUGS
IS5851A (is) Ný lyf til inntöku 5-HT4 gerandefna eða mótlyfja
DE60314265D1 (de) Pharmazeutische zusammensetzungen mit modafinil
HK1038508A1 (en) Dosage form comprising liquid formulation
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen

Legal Events

Date Code Title Description
FB Suspension of granting procedure